WP
DYN icon

Woodline Partners’s Dyne Therapeutics DYN Stock Holding History

Woodline Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.71M Buy
149,388
+28,600
+24% +$493K 0.01% 769
2025
Q4 		$2.36M Buy
+120,788
New +$2.29M 0.01% 753
2025
Q3 		– Sell
-574,853
Closed -$5.47M – 930
2025
Q2 		$5.47M Buy
574,853
+418
+0.1% +$4.6K 0.03% 540
2025
Q1 		$6.01M Buy
574,435
+478
+0.1% +$6.84K 0.04% 456
2024
Q4 		$13.5M Sell
573,957
-403,483
-41% -$11.9M 0.09% 287
2024
Q3 		$35.1M Sell
977,440
-256,468
-21% -$10.2M 0.3% 108
2024
Q2 		$43.5M Buy
1,233,908
+535,981
+77% +$15.6M 0.42% 65
2024
Q1 		$19.8M Buy
697,927
+262,401
+60% +$5.93M 0.18% 173
2023
Q4 		$5.79M Buy
435,526
+99,642
+30% +$973K 0.06% 300
2023
Q3 		$3.01M Sell
335,884
-46,692
-12% -$503K 0.04% 360
2023
Q2 		$4.3M Buy
+382,576
New +$4.51M 0.05% 313
2022
Q3 		– Sell
-666,997
Closed -$4.58M – 773
2022
Q2 		$4.58M Sell
666,997
-146,142
-18% -$1.01M 0.07% 271
2022
Q1 		$7.84M Buy
813,139
+298,538
+58% +$2.54M 0.13% 197
2021
Q4 		$6.12M Buy
514,601
+298,400
+138% +$4.19M 0.09% 260
2021
Q3 		$3.51M Sell
216,201
-6,173
-3% -$109K 0.06% 309
2021
Q2 		$4.68M Sell
222,374
-160,119
-42% -$3.01M 0.09% 231
2021
Q1 		$5.94M Sell
382,493
-108,493
-22% -$2.1M 0.13% 176
2020
Q4 		$10.3M Buy
490,986
+224,187
+84% +$4.43M 0.27% 114
2020
Q3 		$5.39M Buy
+266,799
New +$5.85M 0.18% 123

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Woodline Partners's DYN Position: Q1 2026 in Review

Woodline Partners increased its Dyne Therapeutics (DYN) stake by 24% in Q1 2026, buying an estimated $493K and bringing the position to 149,388 shares worth $2.71M. The position accounts for 0.01% of the portfolio, ranked #769.

Woodline Partners first reported a position in DYN in Q3 2020 and has held it in 19 quarters since. The position peaked at $43.5M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Woodline Partners held 149,388 shares of Dyne Therapeutics worth $2.71M as of Q1 2026.
  • Woodline Partners bought 28,600 Dyne Therapeutics shares in Q1 2026, an estimated $493K.
  • Dyne Therapeutics made up 0.01% of Woodline Partners's portfolio in Q1 2026, its #769 holding.
  • Woodline Partners first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 19 quarters since.
  • Woodline Partners's Dyne Therapeutics position peaked at $43.5M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.